UA97836C2 - Производные плевромутилина для лечения заболеваний, вызванных микробами - Google Patents

Производные плевромутилина для лечения заболеваний, вызванных микробами

Info

Publication number
UA97836C2
UA97836C2 UAA200910582A UAA200910582A UA97836C2 UA 97836 C2 UA97836 C2 UA 97836C2 UA A200910582 A UAA200910582 A UA A200910582A UA A200910582 A UAA200910582 A UA A200910582A UA 97836 C2 UA97836 C2 UA 97836C2
Authority
UA
Ukraine
Prior art keywords
ris
alkyl
cycloalkyl
microbes
treatment
Prior art date
Application number
UAA200910582A
Other languages
English (en)
Ukrainian (uk)
Inventor
Розэмари Манг
Вэрнэр Хэйл-Майер
Рудольф Бадэгрубэр
Дирк Стрикманн
Роджэр Новак
Матиас Фэрэнцик
Атчиута Рама Чандра Мурти Булусу
Original Assignee
Набрива Тэрапэвтикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97836(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Набрива Тэрапэвтикс Аг filed Critical Набрива Тэрапэвтикс Аг
Publication of UA97836C2 publication Critical patent/UA97836C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/98—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members
    • C07C2603/99—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается соединений формулы (I), (I)гдеn равно числу от 0 до 4;m равно 0 или 1, при условии, что атом серы и Rнаходятся в вицинальном положении (если m = 0, тогда Rнаходится в положении 2', а если m = 1, тогда Rнаходится в положении 1');R представляет этил или винил;Rпредставляет атом водорода или (С)алкил,Rпредставляет атом водорода или- (С)циклоалкил, или- незамещенный (С)алкил, или- (С)алкил, замещенный одной или несколькими группами из числа таких, как- гидрокси, преимущественно одна или две,- метокси,- атом галогена,- (С)циклоалкил, илиRи Rвместе с атомом азота, к которому они присоединены, образовывают 5-7-членное гетероциклическое кольцо, которое содержит по меньшей мере 1 атом азота или 1 атом азота и 1 дополнительный
UAA200910582A 2007-03-20 2008-03-19 Производные плевромутилина для лечения заболеваний, вызванных микробами UA97836C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07450053A EP1972618A1 (en) 2007-03-20 2007-03-20 Pleuromutilin derivatives for the treatment of diseases mediated by microbes
PCT/AT2008/000097 WO2008113089A1 (en) 2007-03-20 2008-03-19 Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Publications (1)

Publication Number Publication Date
UA97836C2 true UA97836C2 (ru) 2012-03-26

Family

ID=38668870

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910582A UA97836C2 (ru) 2007-03-20 2008-03-19 Производные плевромутилина для лечения заболеваний, вызванных микробами

Country Status (32)

Country Link
US (12) US20090118366A1 (ru)
EP (3) EP1972618A1 (ru)
JP (2) JP5479114B2 (ru)
KR (1) KR101478593B1 (ru)
CN (2) CN104211624B (ru)
AT (1) ATE523486T1 (ru)
AU (1) AU2008229609B2 (ru)
BR (1) BRPI0809023B8 (ru)
CA (1) CA2678795C (ru)
CY (2) CY1117482T1 (ru)
DK (2) DK2380874T3 (ru)
EA (1) EA018707B1 (ru)
ES (2) ES2375503T3 (ru)
FI (1) FIC20200038I1 (ru)
HK (1) HK1140185A1 (ru)
HR (1) HRP20110869T1 (ru)
HU (1) HUS2100001I1 (ru)
IL (1) IL200440A (ru)
LT (1) LTPA2020531I1 (ru)
MA (1) MA31314B1 (ru)
MY (1) MY148916A (ru)
NL (1) NL301086I2 (ru)
NO (1) NO2021002I1 (ru)
NZ (1) NZ579011A (ru)
PL (1) PL2137143T3 (ru)
PT (2) PT2380874T (ru)
SI (1) SI2137143T1 (ru)
TN (1) TN2009000347A1 (ru)
TW (1) TWI406657B (ru)
UA (1) UA97836C2 (ru)
WO (1) WO2008113089A1 (ru)
ZA (1) ZA200905590B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
WO2010056855A1 (en) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Preparation of retapamulin via its pleuromutilin-thiol precursor
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
EP2433926A1 (en) 2010-09-09 2012-03-28 Nabriva Therapeutics AG Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes
EP2731933B1 (de) 2011-07-15 2015-09-30 Bayer Intellectual Property GmbH 2,3-diphenyl-valeronitrilderivate, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
CN103265487A (zh) * 2013-06-05 2013-08-28 北京理工大学 截短侧耳素扩环衍生物及其制备方法和用途
CN104803911B (zh) * 2014-01-23 2018-01-05 中国科学院上海药物研究所 一类截短侧耳素化合物、其药物组合物、合成方法与用途
ES2553929B1 (es) * 2014-06-11 2016-09-26 Antonio Javier MORENO CASTRO Dispositivo de modificación/destrucción selectiva de tejidos orgánicos
WO2016202788A1 (en) * 2015-06-17 2016-12-22 Nabriva Therapeutics Ag Injectable pharmaceutical formulations of lefamulin
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
NO3106148T3 (ru) 2015-06-18 2018-08-11
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN111170911A (zh) * 2019-09-29 2020-05-19 安帝康（无锡）生物科技有限公司 用于治疗细菌感染性疾病的截短侧耳素类化合物
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
WO2021209596A1 (en) 2020-04-17 2021-10-21 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
CN115397407A (zh) * 2020-04-17 2022-11-25 纳布里瓦治疗有限责任公司 截短侧耳素类化合物的新治疗用途
BR112022020007A2 (pt) * 2020-04-17 2022-11-22 Nabriva Therapeutics GmbH Uso terapêutico de pleuromutilinas
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130709A (en) * 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
DE4023848C2 (de) 1990-07-27 1994-04-21 Huels Chemische Werke Ag Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
MXPA05000984A (es) * 2002-07-24 2005-09-12 Sandoz Ag Derivados de pleuromutilina como antimicrobianos.
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes

Also Published As

Publication number Publication date
NL301086I2 (nl) 2021-01-28
TN2009000347A1 (fr) 2010-12-31
US8153689B2 (en) 2012-04-10
EP2380874A2 (en) 2011-10-26
CY2020032I2 (el) 2020-11-25
CN104211624A (zh) 2014-12-17
US20090118366A1 (en) 2009-05-07
CN101668738B (zh) 2014-10-15
MY148916A (en) 2013-06-14
JP5479114B2 (ja) 2014-04-23
BRPI0809023A2 (pt) 2014-09-23
DK2380874T3 (en) 2017-03-27
LTPA2020531I1 (lt) 2020-11-10
US20220218713A1 (en) 2022-07-14
ES2375503T3 (es) 2012-03-01
KR20090123882A (ko) 2009-12-02
IL200440A0 (en) 2010-04-29
KR101478593B1 (ko) 2015-01-02
US20120029072A1 (en) 2012-02-02
IL200440A (en) 2013-09-30
EP2380874A3 (en) 2011-12-07
ZA200905590B (en) 2010-10-27
HUS2100001I1 (hu) 2021-03-01
US8071643B2 (en) 2011-12-06
CA2678795C (en) 2014-11-18
US20180303842A1 (en) 2018-10-25
US20140256731A1 (en) 2014-09-11
MA31314B1 (fr) 2010-04-01
PT2137143E (pt) 2011-12-22
TWI406657B (zh) 2013-09-01
AU2008229609A1 (en) 2008-09-25
PL2137143T3 (pl) 2012-02-29
JP2014159416A (ja) 2014-09-04
CN104211624B (zh) 2017-12-15
BRPI0809023B8 (pt) 2021-05-25
EP2137143A1 (en) 2009-12-30
JP2010522143A (ja) 2010-07-01
CY1117482T1 (el) 2017-04-26
BRPI0809023B1 (pt) 2020-12-01
US20200030335A1 (en) 2020-01-30
CA2678795A1 (en) 2008-09-25
US20200281933A1 (en) 2020-09-10
AU2008229609B2 (en) 2012-03-29
FIC20200038I1 (fi) 2020-10-01
EA018707B1 (ru) 2013-10-30
ES2620459T3 (es) 2017-06-28
EA200970868A1 (ru) 2010-02-26
WO2008113089A1 (en) 2008-09-25
US20100035987A1 (en) 2010-02-11
CN101668738A (zh) 2010-03-10
US20190175603A1 (en) 2019-06-13
HK1140185A1 (en) 2010-10-08
TW200904402A (en) 2009-02-01
EP2137143B1 (en) 2011-09-07
SI2137143T1 (sl) 2012-01-31
CY2020032I1 (el) 2020-11-25
DK2137143T3 (da) 2012-01-02
PT2380874T (pt) 2017-04-03
EP2380874B1 (en) 2016-12-28
US20130040954A1 (en) 2013-02-14
ATE523486T1 (de) 2011-09-15
NZ579011A (en) 2011-03-31
US20210113571A1 (en) 2021-04-22
NO2021002I1 (no) 2021-01-15
HRP20110869T1 (hr) 2011-12-31
US20170266194A1 (en) 2017-09-21
JP5893651B2 (ja) 2016-03-23
EP1972618A1 (en) 2008-09-24

Similar Documents

Publication Publication Date Title
HUS2100001I1 (hu) Pleuromutilin származékok mikróbák által mediált betegségek kezelésére
MX2012001654A (es) Metodos para usar moduladores de c-met.
MX339823B (es) Ingenol-3-acilatos iii e ingenol-3-carbamatos.
RS20110548A1 (en) TETRACYCLIC UNITS
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
UA105671C2 (ru) Фармацевтическая композиция, которая содержит производное хинолина
MX2008010931A (es) Quinolonas utiles como inhibidores de sintasa de oxido nitrico inducibles.
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
TW200728258A (en) Novel compounds
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MX364833B (es) Sintesis de compuestos polihidroxi cromenona y sus efectos anti-tumor.
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
TW200700071A (en) Novel use
UA97035C2 (ru) Соединения диазенийдиолата, способ их получения и фармацевтическая композиция, которая их содержит
MY162934A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
MY159857A (en) 2,5-substituted oxazolopyrimidine derivatives
MX2009014126A (es) Pirenzepina y derivados de la misma como agentes anti-amiloides.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
GB2483195A (en) Novel uses
MX2011006532A (es) Compuestos anticancerigenos.
MX2010004405A (es) Derivados de pirrolo [1,2-c] imidazol para utilizarse en la profilaxis o tratamiento de cancer que es refractario a terapias cancerigenas conocidas.
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.